The global leader in
design and manufacture of
Bacterial Extracellular Vesicles
The more effective delivery of Bacterial Extracellular Vesicles, or BEVs, at lower cost is critical for the advancement of human health.
The global leader in
design and manufacture of
Bacterial Extracellular Vesicles
The more effective delivery of Bacterial Extracellular Vesicles, or BEVs, at lower cost is critical for the advancement of human health.
The global leader in
design and manufacture of
Bacterial Extracellular Vesicles
The more effective delivery of Bacterial Extracellular Vesicles, or BEVs, at lower cost is critical for the advancement of human health.
Our Mission
Our Mission
From Microbiome to Medicine
From Microbiome to Medicine
At Expora, we radically improve the manufacture and design of Bacterial Extracellular Vesicles (BEVs) to accelerate research and commercialization of BEV therapeutics and health products.
BEVs mediate communication between the microbiome and human cells and hold extraordinary biotechnologic potential. However, commercialization of BEVs has been blocked by lack of scalable manufacturing processes, until now.
Expora makes BEVs dramatically easier to access and simpler to incorporate into product development via proprietary processes to manufacture and design BEVs from beneficial, proven-safe probiotics to meet customer needs across three industries:
Pharma: Therapeutic delivery and cell therapy alternatives. Best-in-class consistency and quality.
Research: Uncover how the microbiome communicates with human cells via production and rigorous characterization of BEVs from virtually any strain.
Consumer: BEVs consistently deliver health benefits of probiotics withiout risks of cells' variable viability/potency. Expora's BEV manufacturing costs are on par with live probiotics (10X improved).
At Expora, we radically improve the manufacture and design of Bacterial Extracellular Vesicles (BEVs) to accelerate research and commercialization of BEV therapeutics and health products.
BEVs mediate communication between the microbiome and human cells and hold extraordinary biotechnologic potential. However, commercialization of BEVs has been blocked by lack of scalable manufacturing processes, until now.
Expora makes BEVs dramatically easier to access and simpler to incorporate into product development via proprietary processes to manufacture and design BEVs from beneficial, proven-safe probiotics to meet customer needs across three industries:
Pharma: Therapeutic delivery and cell therapy alternatives. Best-in-class consistency and quality.
Research: Uncover how the microbiome communicates with human cells via production and rigorous characterization of BEVs from virtually any strain.
Consumer: BEVs consistently deliver health benefits of probiotics withiout risks of cells' variable viability/potency. Expora's BEV manufacturing costs are on par with live probiotics (10X improved).
Bacterial Extracellular Vesicles (BEVs)
Nature's Delivery Vehicles
Bacterial Extracellular Vesicles (BEVs)
Nature's Delivery Vehicles
Bacterial Extracellular Vesicles (BEVs)
Nature's Delivery Vehicles
Our Vision
Our Vision
The gut microbiome controls immunity, brain function, and metabolism, driving an ~$8B probiotics market and emergin pharma applications.
Beneficial bacteria ("probiotics") generate BEVs—nanoscale vesicles that survive the GI tract and deliver potent bioactive cargo directly to gut tissues. But probiotics often underdeliver because they rely on live bacteria surviving manufacturing and storage and producing enough BEVs in vivo, with added safety risks in vulnerable patients.
The field needs a predictable, precise BEV dose at reasonable cost and quality. Until now, BEVs have been too costly and inconsistent to manufacture at scale—Expora’s patent-pending platform changes that by enabling industrial GMP BEV manufacturing and design.
Expora's BEV-enabled advantage:
Expora's BEV-enabled advantage:
Produced by FDA-designated Generally Regarded As Safe (GRAS) probiotics studied in hundreds of clinical trials.
Produced by FDA-designated Generally Regarded As Safe (GRAS) probiotics studied in hundreds of clinical trials.
Oral delivery. Tiny capsule. No injections.
Oral delivery. Tiny capsule. No injections.
Pharma-level quality. Consumer-level affordability.
Pharma-level quality. Consumer-level affordability.
Gut-targeted, multi-specific targeting to meet ideal target product profiles in complex diseases.
Gut-targeted, multi-specific targeting to meet ideal target product profiles in complex diseases.
Our Vision
The gut microbiome controls immunity, brain function, and metabolism, driving an ~$8B probiotics market and emergin pharma applications.
Beneficial bacteria ("probiotics") generate BEVs—nanoscale vesicles that survive the GI tract and deliver potent bioactive cargo directly to gut tissues. But probiotics often underdeliver because they rely on live bacteria surviving manufacturing and storage and producing enough BEVs in vivo, with added safety risks in vulnerable patients.
The field needs a predictable, precise BEV dose at reasonable cost and quality. Until now, BEVs have been too costly and inconsistent to manufacture at scale—Expora’s patent-pending platform changes that by enabling industrial GMP BEV manufacturing and design.
Expora's BEV-enabled advantage:
Produced by FDA-designated Generally Regarded As Safe (GRAS) probiotics studied in hundreds of clinical trials.
Oral delivery. Tiny capsule. No injections.
Pharma-level quality. Consumer-level affordability.
Gut-targeted, multi-specific targeting to meet ideal target product profiles in complex diseases.
Our Vision
Our Vision
The Expora Platform™ overcomes critical EV manufacturing barriers to deliver a transformative new biotechnology modality.
Expora is assembling a talented team to build and scale BEV manufacturing and grow the company at our Maryland-based facility.
We’re actively engaging partners and early investors to advance our BEV platform and products for pharma and consumer health applications. Get in touch to review data and plan next steps.